Vk12653 BioVector®小鼠骨髓瘤细胞系 / Mouse Myeloma Cell Line BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

BioVector® Vk12653 小鼠骨髓瘤细胞系 / Mouse Myeloma Cell Line 数据说明书

产品名称: BioVector® Vk12653 细胞
同义词: BioVector® t-Vk12653; BioVector® Vk12653 骨髓瘤细胞
中文名称: BioVector® Vk12653 小鼠骨髓瘤细胞系
英文名称: BioVector® Vk12653 Mouse Myeloma Cell Line
产品类别: 肿瘤细胞系；多发性骨髓瘤模型
物种来源: 小鼠 (Mus musculus)，C57BL/6 背景
组织来源: 脾脏 (从移植荷瘤小鼠脾脏分离)
细胞类型: 浆细胞 (Plasma cell)
疾病: 多发性骨髓瘤 (Multiple Myeloma)
细胞标志物: CD138+， B220-
构建方法: 来源于 Vk*MYC 转基因小鼠模型的自发性肿瘤，该小鼠携带受免疫球蛋白κ轻链基因增强子控制的 MYC 癌基因，可自发产生与人类多发性骨髓瘤高度相似的浆细胞肿瘤。Vk12653 是经过连续移植和硼替佐米选择建立的移植性细胞系 (t-Vk12653)，通过连续传代在 C57BL/6 小鼠中维持
形态特性: 浆细胞样形态，悬浮生长或轻微贴壁
生长特性: 悬浮生长
特性特征:

1. 分子分型: 根据转录组特征，Vk12653 属于高风险分子分型中的 "Group A" 类别，具有单染色体 5 单体性特征

2. 基因表达特征: 高表达 EMC-92 高风险基因特征，但不表达 UAMS-70 高风险基因特征；具有超增殖、髓外疾病特征

3. 耐药特性: 对硼替佐米 (Bortezomib) 呈部分响应 (partial response)，对维奈托克 (Venetoclax) 具有不同程度的敏感性

4. 免疫特征: 诱导 CD4 和 CD8 T 细胞耗竭

5. 移植模型: 可通过尾静脉注射在免疫健全的 C57BL/6 小鼠中建立系统性多发性骨髓瘤模型，移植后在小鼠血清中可检测到 M 蛋白 (单克隆免疫球蛋白)

6. 药物响应: 在 LCL161 (IAP 拮抗剂) 和抗 CD137 激动剂治疗中显示出响应

7. 体外培养: 在标准培养条件下难以长期扩增，需采用特殊培养条件 (如 3D 悬滴培养、低氧、高密度及细胞因子组合) 以维持细胞存活和功能

8. 基因修饰: 携带 MYC 转基因，可通过 Cre-loxP 系统调控
   研究应用:

9. 多发性骨髓瘤发病机制研究

10. 高风险骨髓瘤分子分型研究

11. 耐药机制研究 (硼替佐米部分响应模型)

12. 免疫治疗评估 (抗 CD137 激动剂、IAP 拮抗剂等)

13. 联合治疗策略开发

14. 肿瘤微环境与免疫细胞相互作用研究

15. 铁代谢与骨髓瘤关系研究

16. 药物筛选与疗效评估
    培养基: BioVector® Vk12653 细胞专用完全培养基（推荐基础成分：RPMI-1640 培养基，添加 10-20% 胎牛血清、1% 青霉素-链霉素、2mM L-谷氨酰胺、1mM 丙酮酸钠，以及细胞因子组合如 IL-6 等）
    培养条件: 气相：95% 空气，5% 二氧化碳；温度：37°C；推荐低氧培养 (6.5% O₂) 以增强细胞存活
    传代方法: 细胞对培养条件敏感，常规传代困难。推荐使用 BioVector® 专用培养体系，在 3D 悬滴或低氧条件下维持培养，每 2-3 天补充新鲜培养基
    冻存液: BioVector® 细胞冻存液（推荐配方：90% 胎牛血清 + 10% DMSO）
    质量控制: 支原体检测：阴性；无菌检测：阴性；体内成瘤能力验证：阳性；M 蛋白检测：阳性
    储存与运输: 液氮或干冰运输与保存
    生物安全等级: 1（需在二级生物安全柜内操作）
    仅供科研使用

English:
BioVector® Vk12653 Mouse Myeloma Cell Line Datasheet

Product Name: BioVector® Vk12653 Cells
Synonyms: BioVector® t-Vk12653; BioVector® Vk12653 Myeloma Cells
Chinese Name: BioVector® Vk12653 小鼠骨髓瘤细胞系
English Name: BioVector® Vk12653 Mouse Myeloma Cell Line
Product Category: Cancer Cell Line; Multiple Myeloma Model
Species of Origin: Mouse (Mus musculus), C57BL/6 background
Tissue of Origin: Spleen (isolated from spleens of transplanted tumor-bearing mice)
Cell Type: Plasma cell
Disease: Multiple Myeloma
Cell Markers: CD138+, B220-
Derivation: Derived from spontaneous tumors arising in the Vk*MYC transgenic mouse model, which carries the MYC oncogene under control of the immunoglobulin kappa light chain gene enhancer and spontaneously develops plasma cell tumors highly similar to human multiple myeloma. Vk12653 is a transplantable cell line (t-Vk12653) established through serial transplantation and bortezomib selection, maintained in C57BL/6 mice by serial passage
Morphology: Plasma cell-like morphology, suspension or weak adherent growth
Growth Characteristics: Suspension growth
Characteristics:

1. Molecular Subtype: Classified as "Group A" within high-risk molecular subtypes based on transcriptomic profiling, characterized by monosomy of chromosome 5

2. Gene Expression Profile: High expression of EMC-92 high-risk gene signature, but not UAMS-70 high-risk gene signature; features include hyperproliferation and extramedullary disease

3. Drug Resistance: Exhibits partial response to Bortezomib; variable sensitivity to Venetoclax

4. Immune Characteristics: Induces CD4 and CD8 T cell exhaustion

5. Transplant Model: Can establish systemic multiple myeloma in immunocompetent C57BL/6 mice via intravenous tail vein injection; M-protein (monoclonal immunoglobulin) detectable in mouse serum after transplantation

6. Drug Response: Shows response to LCL161 (IAP antagonist) and anti-CD137 agonist therapy

7. In Vitro Culture: Difficult to expand in standard culture conditions; requires specialized culture conditions (e.g., 3D hanging drop culture, hypoxia, high density, cytokine cocktail) to maintain cell viability and function

8. Genetic Modification: Carries MYC transgene that can be regulated by Cre-loxP system
   Research Applications:

9. Multiple myeloma pathogenesis studies

10. High-risk myeloma molecular subtyping research

11. Drug resistance mechanism studies (partial bortezomib response model)

12. Immunotherapy evaluation (anti-CD137 agonists, IAP antagonists, etc.)

13. Combination therapy strategy development

14. Tumor microenvironment and immune cell interaction studies

15. Iron metabolism and myeloma relationship studies

16. Drug screening and efficacy evaluation
    Culture Medium: BioVector® Complete Medium for Vk12653 Cells (Recommended composition: RPMI-1640 medium supplemented with 10-20% fetal bovine serum, 1% penicillin-streptomycin, 2mM L-glutamine, 1mM sodium pyruvate, and cytokine cocktail such as IL-6)
    Culture Conditions: Atmosphere: 95% air, 5% CO₂; Temperature: 37°C; Hypoxic culture (6.5% O₂) recommended to enhance cell survival
    Subculturing Method: Cells are sensitive to culture conditions; conventional passaging is difficult. Recommended to use BioVector® Specialized Culture System and maintain under 3D hanging drop or hypoxic conditions; replenish with fresh medium every 2-3 days
    Freeze Medium: BioVector® Cell Freeze Medium (Recommended composition: 90% FBS + 10% DMSO)
    Quality Control: Mycoplasma: Negative; Sterility: Negative; In Vivo Tumorigenicity Validation: Positive; M-protein Detection: Positive
    Storage and Shipment: Stored and shipped in liquid nitrogen or on dry ice
    Biosafety Level: 1 (Operate in a Class II biological safety cabinet)
    For Research Use Only

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址http://www.biovector.net